## **REMARKS**

By a Final Office Action dated May 24, 2005 in the file of the above-identified application, the Examiner rejected this application on a variety of grounds. By submission of this response, reconsideration of the merits of this rejection is respectfully requested.

First in the Office Action, the Examiner had requested that the word GENEARRAY be used in a way so as to indicate its trademark status. That change has been made to the specification above.

On paragraph 5 of the Office Action the Examiner had a series of claim rejections to the word because of grammatical informalities and because the applicants were referring to proteins as genes. It is believed those errors have been corrected in the amendments to the claims made above.

In paragraph 7 of the Office Action the Examiner rejected the claims for the reasons set forth in the prior office action. The applicants continue to assert that the mouse model used in the data described in this patent application is a common accepted model to investigate insulin sensitivity and progression of diabetes. The Examiner continues to disagree. Nevertheless, the applicants continue to believe that the arguments made on this position will be taken and reconsideration of the merits of this rejection is respectfully requested.

The rejection contained in paragraph 8 of the Office Action related to the recitation of the molecule aa667872 has been rendered moot by withdrawal of the language to that gene from the claims above.

Beginning on page 6 of the Office Action were a series of new rejections based on language issues imposed by the Examiner based on changes made by the applicants in the last office action. In essence, the Examiner felt that the applicants had not provided a clear comparison of examples for the language used in the claims. By changes to the claims made above, the applicants have responded to each of these grounds of rejection and added comparative language to the claims. It is believed that the changes to the claims made above fully and completely address this issue.

Wherefore reconsideration of the merits of this patent application is respectfully requested.

A Request for Continued Examination is filed herewith. Please charge the fee to Deposit Account No. 17-0055.

A separate petition for extension of time is submitted herewith so that this response will be considered as timely filed. Please charge the fee to Deposit Account No. 17-0055.

Respectfully submitted,

Nieholas J. Sear

Reg. No.: 27,386

Attorney for Applicants
QUARLES & BRADY LLP

P.O. Box 2113 Madison, WI 53701

TEL 608/251-5000 FAX 608/251-9166

-7-